Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ymthe.2017.03.023 http://scihub22266oqcxt.onion/10.1016/j.ymthe.2017.03.023 C5417833!5417833 !28366767     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28366767 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Mol+Ther 2017 ; 25 (5 ): 1069-1075 Nephropedia Template TP {{tp|p=28366767 |t=2017. FDA-Approved Oligonucleotide Therapies in 2017 |pdf=|usr=}}{{28366767 }} gab.com Text FDA-Approved Oligonucleotide Therapies in 2017 JO: Mol Ther http://www.kidney.de/pget.php?&tw=1&pmid=28366767 #FOAvip Oligonucleotides (oligos) have been under clinical development for approximately the past 30 years, beginning with antisense oligonucleotides (ASOs) and apatmers and followed about 15 years ago by siRNAs. During that lengthy period of time, numerous clinical trials have been performed and thousands of trial participants accrued onto studies. Of all the molecules evaluated as of January 2017, the regulatory authorities assessed that six provided clear clinical benefit in rigorously controlled trials. The story of these six is given in this review. Twit Text FOAVip FDA-Approved Oligonucleotide Therapies in 2017 ????Mol Ther http://www.kidney.de/pget.php?&tw=1&pmid=28366767 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28366767 #FOAvip English Wikipedia <ref>{{Cite pmid|28366767 }}</ref> FDA-Approved Oligonucleotide Therapies in 2017 #MMPMID28366767 Stein CA ; Castanotto D Mol Ther 2017[May]; 25 (5 ): 1069-1075 PMID28366767 show ga Oligonucleotides (oligos) have been under clinical development for approximately the past 30 years, beginning with antisense oligonucleotides (ASOs) and apatmers and followed about 15 years ago by siRNAs. During that lengthy period of time, numerous clinical trials have been performed and thousands of trial participants accrued onto studies. Of all the molecules evaluated as of January 2017, the regulatory authorities assessed that six provided clear clinical benefit in rigorously controlled trials. The story of these six is given in this review. |Aptamers, Nucleotide/*therapeutic use [MESH] |Clinical Trials as Topic [MESH] |Cytomegalovirus Retinitis/genetics/therapy/virology [MESH] |Drug Approval [MESH] |Hepatic Veno-Occlusive Disease/genetics/pathology/therapy [MESH] |Humans [MESH] |Hypercholesterolemia/genetics/pathology/therapy [MESH] |Macular Degeneration/genetics/pathology/therapy [MESH] |Morpholinos/*therapeutic use [MESH] |Muscular Atrophy, Spinal/genetics/pathology/therapy [MESH] |Muscular Dystrophy, Duchenne/genetics/pathology/therapy [MESH] |Oligonucleotides, Antisense/*therapeutic use [MESH] |Oligonucleotides/*therapeutic use [MESH] |Polydeoxyribonucleotides/*therapeutic use [MESH]FDA-Approved Oligonucleotide Therapies in 2017 (epmc).pdf DeepDyve Pubget Overpricing